PT2028186E - Tripéptidos inibidores da hepatite c - Google Patents

Tripéptidos inibidores da hepatite c

Info

Publication number
PT2028186E
PT2028186E PT81690265T PT08169026T PT2028186E PT 2028186 E PT2028186 E PT 2028186E PT 81690265 T PT81690265 T PT 81690265T PT 08169026 T PT08169026 T PT 08169026T PT 2028186 E PT2028186 E PT 2028186E
Authority
PT
Portugal
Prior art keywords
hepatitis
peptides
inhibitor tri
tri
inhibitor
Prior art date
Application number
PT81690265T
Other languages
English (en)
Portuguese (pt)
Inventor
Bruno Simoneau
Murray D Bailey
Montse As-Brunet
Dale Cameron
Anne-Marie Faucher
Dominik M Wernic
Nathalie Goudreau
Marc-Andre Poupart
Jean Rancourt
Youla S Tsantrizos
Teddy Halmos
Elise Ghiro
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of PT2028186E publication Critical patent/PT2028186E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT81690265T 1998-08-10 1999-08-09 Tripéptidos inibidores da hepatite c PT2028186E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9593198P 1998-08-10 1998-08-10
US13238699P 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
PT2028186E true PT2028186E (pt) 2013-03-27

Family

ID=26790767

Family Applications (2)

Application Number Title Priority Date Filing Date
PT81690265T PT2028186E (pt) 1998-08-10 1999-08-09 Tripéptidos inibidores da hepatite c
PT99938084T PT1105413E (pt) 1998-08-10 1999-08-09 Tripéptidos inibidores da hepatite c

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT99938084T PT1105413E (pt) 1998-08-10 1999-08-09 Tripéptidos inibidores da hepatite c

Country Status (43)

Country Link
US (11) US6323180B1 (OSRAM)
EP (2) EP1105413B1 (OSRAM)
JP (2) JP4485685B2 (OSRAM)
KR (2) KR100672229B1 (OSRAM)
CN (2) CN100339389C (OSRAM)
AR (3) AR020880A1 (OSRAM)
AT (1) ATE430158T1 (OSRAM)
AU (1) AU769738B2 (OSRAM)
BG (1) BG65738B1 (OSRAM)
BR (2) BRPI9913646B8 (OSRAM)
CA (2) CA2445938C (OSRAM)
CO (1) CO5261542A1 (OSRAM)
CY (2) CY1109291T1 (OSRAM)
CZ (2) CZ302766B6 (OSRAM)
DE (1) DE69940817D1 (OSRAM)
DK (2) DK2028186T3 (OSRAM)
EA (1) EA003906B1 (OSRAM)
EE (1) EE05517B1 (OSRAM)
ES (2) ES2326707T3 (OSRAM)
HK (1) HK1040085B (OSRAM)
HR (1) HRP20010102B1 (OSRAM)
HU (2) HU230701B1 (OSRAM)
ID (1) ID27839A (OSRAM)
IL (3) IL141012A0 (OSRAM)
IN (3) IN211493B (OSRAM)
ME (1) ME00381B (OSRAM)
MX (2) MX261584B (OSRAM)
MY (1) MY127538A (OSRAM)
NO (2) NO328952B1 (OSRAM)
NZ (1) NZ510396A (OSRAM)
PE (1) PE20000949A1 (OSRAM)
PH (1) PH11999002002B1 (OSRAM)
PL (1) PL204850B1 (OSRAM)
PT (2) PT2028186E (OSRAM)
RS (3) RS50798B (OSRAM)
SA (1) SA99200617B1 (OSRAM)
SI (2) SI2028186T1 (OSRAM)
SK (2) SK288068B6 (OSRAM)
TR (2) TR200100432T2 (OSRAM)
TW (1) TWI250165B (OSRAM)
UA (1) UA75026C2 (OSRAM)
WO (1) WO2000009543A2 (OSRAM)
ZA (1) ZA200100971B (OSRAM)

Families Citing this family (423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21649A (id) 1996-10-18 1999-07-08 Vertex Pharma Inhibitor serum protease, terutama virus hepatitis c ns3 protease
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
EP1257649B1 (en) * 1999-06-25 2010-01-20 Paik Kwang Industrial Co., Ltd. Corynebacterium glutamicum genes encoding metabolic pathway proteins
DE60137207D1 (de) 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
KR20020097220A (ko) 2000-04-19 2002-12-31 쉐링 코포레이션 알킬 및 아릴 알라닌 ｐ2 잔기를 포함하는 ｃ형 간염바이러스의 매크로사이클릭 ｎｓ3-세린 프로테아제 억제제
WO2001085720A1 (en) 2000-05-05 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PL365695A1 (en) 2000-07-21 2005-01-10 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
MY139078A (en) 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
US6872805B2 (en) 2000-11-20 2005-03-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2324594T3 (es) 2000-12-12 2009-08-11 Schering Corporation Diaril peptidicos utilizados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
EA007491B1 (ru) 2001-01-22 2006-10-27 Мерк Энд Ко., Инк. Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
DE60217114T2 (de) 2001-07-11 2007-10-25 Vertex Pharmaceuticals Inc., Cambridge Verbrückte bizyklische serinproteaseinhibitoren
CN1289338C (zh) 2001-09-14 2006-12-13 本田技研工业株式会社 用于车辆的前格栅碰撞缓冲结构
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
JP2005511572A (ja) * 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
JP4301953B2 (ja) 2002-01-23 2009-07-22 シェーリング コーポレイション Ｃ型肝炎ウイルス感染の処置における使用のためのｎｓ３−セリンプロテアーゼ阻害剤としてのプロリン化合物
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
NZ575692A (en) 2002-04-11 2009-10-30 Vertex Pharma Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003299519A1 (en) * 2002-05-20 2004-05-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
ES2315568T3 (es) * 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
ES2350201T3 (es) * 2002-05-20 2011-01-20 Bristol-Myers Squibb Company Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
KR100457857B1 (ko) * 2002-05-23 2004-11-18 (주) 비엔씨바이오팜 2-[2-(3-인돌릴)에틸아미노]피리딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US7183302B2 (en) * 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
EP1408031A1 (en) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
TW200418848A (en) 2002-10-24 2004-10-01 Glaxo Group Ltd Compounds
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1601685A1 (en) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
EP1599496B1 (en) * 2003-03-05 2010-11-03 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
KR100960802B1 (ko) * 2003-03-08 2010-06-01 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
DE602004019518D1 (de) * 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
DE602004023924D1 (en) * 2003-04-18 2009-12-17 Enanta Pharm Inc Ease-hemmer
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
KR101115294B1 (ko) * 2003-05-21 2012-04-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 억제제 화합물
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
WO2004113365A2 (en) * 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
EP1658302B1 (en) * 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
JP4527722B2 (ja) 2003-08-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
CN1856502A (zh) * 2003-09-22 2006-11-01 贝林格尔.英格海姆国际有限公司 抗c型肝炎病毒活性的巨环肽
AR046166A1 (es) 2003-09-26 2005-11-30 Schering Corp Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005042570A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005051980A1 (en) * 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE602004019973D1 (de) * 2003-12-08 2009-04-23 Boehringer Ingelheim Int Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
WO2005058884A2 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
ATE495185T1 (de) * 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
ES2336009T3 (es) * 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
SE0400199D0 (sv) * 2004-01-30 2004-01-30 Medivir Ab HCV Protease inhbitors
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1718608B1 (en) 2004-02-20 2013-07-17 Boehringer Ingelheim International GmbH Viral polymerase inhibitors
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ES2322602T3 (es) 2004-02-24 2009-06-23 Japan Tobacco, Inc. Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
CA2557301A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1730165A1 (en) 2004-02-27 2006-12-13 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
DE602005015834D1 (de) 2004-02-27 2009-09-17 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005015093D1 (de) 2004-02-27 2009-08-06 Schering Corp Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
BRPI0508085A (pt) * 2004-02-27 2007-07-17 Schering Corp compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
KR20060127162A (ko) 2004-02-27 2006-12-11 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의화합물
DK1725548T3 (en) * 2004-03-12 2015-03-23 Vertex Pharma Process and intermediates for the preparation of asparagine acetal caspase inhibitors
AU2005224092A1 (en) * 2004-03-15 2005-09-29 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis C viral infections
WO2005095403A2 (en) * 2004-03-30 2005-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
EP1773868B1 (en) 2004-05-20 2009-07-15 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
EP1753775B1 (en) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006012078A2 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7705146B2 (en) * 2004-06-28 2010-04-27 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor peptide analogs
AR050174A1 (es) * 2004-07-16 2006-10-04 Gilead Sciences Inc Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006007708A1 (en) * 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
SI3109244T1 (sl) * 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
BRPI0516825A (pt) 2004-10-01 2008-09-23 Vertex Pharma inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1863833T3 (da) 2005-03-08 2013-12-02 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af makrocykliske forbindelser
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
PE20070011A1 (es) * 2005-06-02 2007-03-08 Schering Corp Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
JP2008546708A (ja) 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
ZA200711069B (en) * 2005-06-30 2009-03-25 Virobay Inc HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2615921C (en) * 2005-07-20 2011-09-13 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP2305696A3 (en) * 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
US7666834B2 (en) 2005-07-29 2010-02-23 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis C virus
BRPI0614638A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para a preparação dos mesmos, combinação e composição farmacêutica
EP1912996B1 (en) 2005-07-29 2012-06-20 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
ATE524475T1 (de) 2005-07-29 2011-09-15 Tibotec Pharm Ltd Makrocyclische inhibitoren des hepatitis-c-virus
MX2008001402A (es) 2005-07-29 2008-04-04 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c.
MY141245A (en) 2005-07-29 2010-03-31 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007016441A1 (en) * 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2618560A1 (en) 2005-08-09 2007-02-22 Merck & Co., Inc. Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection
WO2007019674A1 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
PT2194043E (pt) * 2005-08-19 2014-03-04 Vertex Pharma Processos
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DK1934243T3 (da) 2005-09-09 2011-09-05 Boehringer Ingelheim Int Cykliserende metathesefremgangsmåde til fremstilling af makrocykliske peptider
JP2009511595A (ja) 2005-10-11 2009-03-19 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルスの複製を阻害する化合物および方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392590A3 (en) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7763731B2 (en) 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
WO2007103550A2 (en) 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-hcv activity
US20070225297A1 (en) 2006-03-16 2007-09-27 Perni Robert B Deuterated hepatitis C protease inhibitors
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
RU2419626C2 (ru) 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US8268776B2 (en) 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) * 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
TWI454264B (zh) * 2006-06-26 2014-10-01 Enanta Pharm Inc 喹啉基巨環ｃ型肝炎病毒絲胺酸蛋白酶抑制劑
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008022006A2 (en) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CA2660555A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
JP5345941B2 (ja) * 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2667146C (en) * 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8377873B2 (en) * 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8377874B2 (en) * 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
KR101615500B1 (ko) * 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080108632A1 (en) * 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321677B2 (en) 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2009005219A (es) 2006-11-17 2009-05-27 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de hepatitis c.
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
WO2008133753A2 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
GB0625345D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) * 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
WO2008095058A1 (en) * 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
DK2114924T3 (da) 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
EP2144604B1 (en) 2007-02-28 2011-09-21 Conatus Pharmaceuticals, Inc. Methods for the treatment of chronic viral hepatitis C using RO 113-0830
MX2009010205A (es) * 2007-03-23 2009-10-19 Schering Corp Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20080292587A1 (en) * 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20080317712A1 (en) * 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
BRPI0811020A2 (pt) * 2007-05-03 2015-07-21 Intermune Inc Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral.
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
CA2685888A1 (en) * 2007-05-09 2008-11-20 Pfizer Inc. Substituted heterocyclic derivatives and their pharmaceutical use and compositions
KR20100027134A (ko) 2007-05-10 2010-03-10 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
EP2162431B1 (en) * 2007-06-29 2017-06-07 Gilead Sciences, Inc. Antiviral compounds
AU2008271117B2 (en) 2007-06-29 2013-10-24 Gilead Sciences, Inc. Antiviral compounds
AU2008277440A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
JP5433573B2 (ja) * 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
MX2010002407A (es) 2007-08-30 2010-03-26 Vertex Pharma Cocristales y composiciones farmaceuticas que los comprenden.
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
WO2009064955A1 (en) 2007-11-14 2009-05-22 Enanta Pharmaceuticals, Inc. Macrocyclic tetrazolyl hepatitis c serine protease inhibitors
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
WO2009076166A2 (en) * 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
CA2708150A1 (en) * 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
WO2009073780A1 (en) 2007-12-06 2009-06-11 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis c protease inhibitors
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010008108A (es) * 2008-01-24 2010-09-22 Enanta Pharm Inc Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.
MX2010008109A (es) * 2008-01-24 2010-09-22 Enanta Pharm Inc Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
CN101977915B (zh) 2008-02-04 2014-08-13 埃迪尼克斯医药公司 大环丝氨酸蛋白酶抑制剂
JP5718647B2 (ja) 2008-02-07 2015-05-13 ビロベイ，インコーポレイティド カテプシンｂの阻害剤
EP2268285B1 (en) 2008-02-25 2018-06-27 Merck Sharp & Dohme Corp. Therapeutic compounds
JP5490778B2 (ja) * 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2282762A2 (en) 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009241445A1 (en) * 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2009134987A1 (en) * 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
US20090285774A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100003217A1 (en) 2008-07-02 2010-01-07 Erika Cretton-Scott Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
PT2310095E (pt) 2008-07-22 2012-11-16 Angeletti P Ist Richerche Bio Compostos de quinoxalina macrocílicos como inibidores da protease ns3 do hcv
KR20110033291A (ko) 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR101653550B1 (ko) * 2008-09-16 2016-09-02 베링거 인겔하임 인터내셔날 게엠베하 강력한 ｈｃｖ 억제제인 2-티아졸릴-4-퀴놀리닐-옥시 유도체의 결정 형태
BRPI0918653A2 (pt) * 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
CA2736472A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2341924A4 (en) 2008-10-02 2013-01-23 David Gladstone Inst METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
CA2740728A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
KR20110074941A (ko) 2008-10-30 2011-07-04 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 아릴피리돈 유도체
HRP20140097T1 (hr) * 2008-11-21 2014-03-14 Boehringer Ingelheim International Gmbh Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu
PL2373172T3 (pl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals Inc Inhibitory HCV NS5A
JP2012510523A (ja) 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0923184A2 (pt) 2008-12-19 2019-09-24 Gilead Sciences Inc inibidores de hcv ns3 protease
WO2010075127A1 (en) 2008-12-22 2010-07-01 Gilead Sciences, Inc. Antiviral compounds
WO2010072598A1 (en) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
MX2011008641A (es) 2009-03-06 2011-09-06 Hoffmann La Roche Compuestos heterociclicos antivirales.
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
SG175774A1 (en) 2009-04-25 2011-12-29 Hoffmann La Roche Heterocyclic antiviral compounds
WO2010132163A1 (en) 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
TWI428332B (zh) * 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
EP2445875A2 (en) 2009-06-24 2012-05-02 F. Hoffmann-La Roche AG Heterocyclic antiviral compound
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
EP2448912A4 (en) * 2009-07-02 2014-05-28 Reddys Lab Ltd Dr ENZYMES AND METHODS FOR DEDOLDING AMINOVINYL-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011019066A1 (ja) * 2009-08-10 2011-02-17 住友化学株式会社 光学活性な１－アミノ－２－ビニルシクロプロパンカルボン酸エステルの製造方法
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
SG179566A1 (en) * 2009-09-15 2012-05-30 Taigen Biotechnology Co Ltd Hcv protease inhibitors
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
TW201119667A (en) * 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
MX2012007420A (es) 2009-12-24 2012-07-23 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones de flavivirus.
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8653025B2 (en) 2010-01-27 2014-02-18 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
NZ703416A (en) 2010-09-21 2016-06-24 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US20120135949A1 (en) * 2010-09-30 2012-05-31 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
MX2013006951A (es) * 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
EP2725012A1 (en) 2011-06-21 2014-04-30 Mitsubishi Gas Chemical Company, Inc. 1-amino-2-vinyl cyclopropane carboxylic acid amide, salt of same, and method for producing same
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
CN102807607B (zh) * 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
DE102012016127A1 (de) 2011-08-31 2013-02-28 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
JP2014526474A (ja) 2011-09-12 2014-10-06 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2847083A1 (en) 2011-10-10 2013-04-18 F. Hoffmann-La Roche Ag Antiviral compounds
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI532487B (zh) 2011-10-21 2016-05-11 艾伯維有限公司 治療ｃ型肝炎病毒（ｈｃｖ）之方法
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN107898790B (zh) 2011-11-30 2024-06-21 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
CN104066432B (zh) 2011-12-06 2017-06-13 小利兰·斯坦福大学董事会 用于治疗病毒性疾病的方法和组合物
MX2014006745A (es) 2011-12-16 2014-10-15 Hoffmann La Roche Inhibidores de hcv ns5a.
LT2794628T (lt) 2011-12-20 2017-07-10 Riboscience Llc 4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai
PT2794629T (pt) 2011-12-20 2017-07-20 Riboscience Llc Derivados de nucleósidos substituídos em 2¿-4¿-difluor-2¿-metilo, como inibidores da replicação do arn de vhc (vírus da hepatite c)
WO2013106506A1 (en) 2012-01-12 2013-07-18 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent hcv inhibitor
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
US9090559B2 (en) 2012-02-24 2015-07-28 Hoffmann-La Roche Inc. Antiviral compounds
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
EA030189B8 (ru) 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс Аналоги 2'-хлоронуклеозидов для инфекции вгс
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
CN103804208B (zh) * 2012-11-14 2016-06-08 重庆博腾制药科技股份有限公司 一种丙肝药物中间体的制备方法
EP2938624A1 (en) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
KR20150109451A (ko) 2013-01-23 2015-10-01 에프. 호프만-라 로슈 아게 항바이러스성 트라이아졸 유도체
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
KR20150114566A (ko) 2013-03-05 2015-10-12 에프. 호프만-라 로슈 아게 항바이러스 화합물
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
CA2905433A1 (en) * 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
SG11201509427RA (en) 2013-05-16 2015-12-30 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
WO2014186637A1 (en) 2013-05-16 2014-11-20 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US9717797B2 (en) 2013-12-05 2017-08-01 International Business Machines Corporation Polycarbonates bearing aromatic N-heterocycles for drug delivery
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066795A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
TWI860279B (zh) 2017-09-21 2024-11-01 美商里伯賽恩斯有限責任公司 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) * 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
JPH05155827A (ja) * 1991-12-09 1993-06-22 Banyu Pharmaceut Co Ltd ｃｉｓ−２−アミノシクロプロパンカルボン酸誘導体の製造法
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
CN1141591A (zh) * 1994-02-23 1997-01-29 布·安格莱荻公司分子生物学研究所 体外再生丙型肝炎病毒(hcv)ns3蛋白酶的解蛋白活性的方法
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
CA2165996C (en) * 1995-12-22 2002-01-29 Murray Douglas Bailey Stereoselective preparation of 2-substituted succinic derivatives
DE19600034C2 (de) 1996-01-02 2003-12-24 Degussa 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
ID21649A (id) 1996-10-18 1999-07-08 Vertex Pharma Inhibitor serum protease, terutama virus hepatitis c ns3 protease
WO1998053814A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
HUP0004853A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
US6455571B1 (en) * 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
DE19835120C1 (de) * 1998-08-04 1999-10-21 Westfalia Separator Ag Verfahren und Vorrichtung zum Einstellen des Flüssigkeitsgehalts des aus einer selbstentleerenden Schleudertrommel eines Separators ausgetragenen Feststoffes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
EP1599496B1 (en) * 2003-03-05 2010-11-03 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
EP1601685A1 (en) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds

Also Published As

Publication number Publication date
MXPA01001423A (es) 2001-08-01
SA99200617B1 (ar) 2006-06-24
ME00381B (me) 2011-10-10
IL196545A0 (en) 2011-07-31
MEP58508A (en) 2011-05-10
NZ510396A (en) 2004-02-27
US6420380B2 (en) 2002-07-16
ES2405930T3 (es) 2013-06-04
CA2445938A1 (en) 2000-02-24
US6410531B1 (en) 2002-06-25
CZ2001516A3 (cs) 2001-08-15
EA200100228A1 (ru) 2001-10-22
ATE430158T1 (de) 2009-05-15
PH11999002002B1 (en) 2007-10-19
CZ302766B6 (cs) 2011-10-26
JP4485685B2 (ja) 2010-06-23
HUP0105144A3 (en) 2002-11-28
UA75026C2 (en) 2006-03-15
USRE41356E1 (en) 2010-05-25
PE20000949A1 (es) 2000-09-26
BR9913646A (pt) 2001-06-05
US20020016442A1 (en) 2002-02-07
NO336663B1 (no) 2015-10-12
EP1105413A2 (en) 2001-06-13
YU9401A (sh) 2003-02-28
CN101143892B (zh) 2010-12-08
TWI250165B (en) 2006-03-01
HU230701B1 (hu) 2017-10-30
NO20100004L (no) 2001-04-02
HK1040085A1 (zh) 2002-05-24
NO328952B1 (no) 2010-06-28
EP2028186A2 (en) 2009-02-25
HRP20010102B1 (en) 2010-07-31
AR073428A2 (es) 2010-11-03
CO5261542A1 (es) 2003-03-31
AU5273199A (en) 2000-03-06
ID27839A (id) 2001-04-26
WO2000009543A3 (en) 2000-05-25
US20020037998A1 (en) 2002-03-28
WO2000009543A2 (en) 2000-02-24
HK1040085B (zh) 2008-05-30
IN211493B (OSRAM) 2008-01-25
IL141012A (en) 2009-09-01
IN2001MU00127A (OSRAM) 2005-03-04
EP2028186A3 (en) 2009-04-01
EE05517B1 (et) 2012-02-15
US6329379B1 (en) 2001-12-11
SK2062001A3 (en) 2001-10-08
NO20010683L (no) 2001-04-02
NO20010683D0 (no) 2001-02-09
KR100631439B1 (ko) 2006-10-09
TR200100432T2 (tr) 2001-09-21
CA2338946A1 (en) 2000-02-24
SK288068B6 (sk) 2013-05-03
BG105232A (en) 2001-11-30
US6268207B1 (en) 2001-07-31
SI2028186T1 (sl) 2013-06-28
CA2338946C (en) 2010-10-12
CY1109291T1 (el) 2014-07-02
RS53562B1 (sr) 2015-02-27
BG65738B1 (bg) 2009-09-30
DE69940817D1 (en) 2009-06-10
PT1105413E (pt) 2009-06-30
ZA200100971B (en) 2002-06-26
DK1105413T3 (da) 2009-08-17
HRP20010102A2 (en) 2002-02-28
IL141012A0 (en) 2002-02-10
SK286994B6 (sk) 2009-09-07
CZ301268B6 (cs) 2009-12-30
TR200200129T2 (tr) 2002-06-21
EA003906B1 (ru) 2003-10-30
USRE42164E1 (en) 2011-02-22
CA2445938C (en) 2012-10-30
IL196545A (en) 2012-06-28
PL204850B1 (pl) 2010-02-26
SI1105413T1 (sl) 2009-10-31
ES2326707T3 (es) 2009-10-16
US6323180B1 (en) 2001-11-27
PL346626A1 (en) 2002-02-25
DK2028186T3 (da) 2013-03-25
MY127538A (en) 2006-12-29
MX261584B (es) 2008-10-22
USRE41894E1 (en) 2010-10-26
HK1113164A1 (en) 2008-09-26
EP1105413B1 (en) 2009-04-29
KR20060083992A (ko) 2006-07-21
SA99200617A (ar) 2005-12-03
KR20010085363A (ko) 2001-09-07
MX257413B (es) 2008-05-27
CY1113935T1 (el) 2016-07-27
USRE40525E1 (en) 2008-09-30
HU229262B1 (en) 2013-10-28
HUP1300080A2 (OSRAM) 2002-04-29
JP2002522554A (ja) 2002-07-23
BR9917805B1 (pt) 2014-06-17
RS20090459A (sr) 2010-06-30
JP5021711B2 (ja) 2012-09-12
RS50798B (sr) 2010-08-31
BRPI9913646B8 (pt) 2021-05-25
HUP0105144A2 (hu) 2002-04-29
EP2028186B1 (en) 2013-01-23
CN100339389C (zh) 2007-09-26
BR9913646B1 (pt) 2014-12-02
CN1323316A (zh) 2001-11-21
IN2007MU00706A (OSRAM) 2007-07-20
AU769738B2 (en) 2004-02-05
EE200100081A (et) 2002-08-15
AR069583A2 (es) 2010-02-03
AR020880A1 (es) 2002-06-05
CN101143892A (zh) 2008-03-19
US6534523B1 (en) 2003-03-18
KR100672229B1 (ko) 2007-02-28
JP2010043124A (ja) 2010-02-25
US6329417B1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
PH11999002002B1 (en) Hepatitis C inhibitor tri-peptides
DE69929887D1 (en) Hepatitis c inhibitor peptide
GB9707659D0 (en) Hepatitis C NS3 Protease inhibitors
ZA98376B (en) Sulfamide-metalloprotease inhibitors
GB2321641B (en) Sulfamide-metalloprotease inhibitors
IL139269A0 (en) Hepatitis vaccine
GB2389113B (en) B-secretase inhibitor
GB9827877D0 (en) Mudguard
GB2341161B (en) Mudguard
SI0952982T1 (en) Novel hepatitis b inhibitors
GB9828697D0 (en) Inhibitors
GB9826992D0 (en) Inhibitors
GB9803416D0 (en) Inhibitors
GB9705552D0 (en) Elastase inhibitor
GB9717893D0 (en) Inhibitor
GB9707219D0 (en) Inhibitor
GB9709064D0 (en) Inhibitors
GB9713709D0 (en) Inhibitors
GB9725783D0 (en) Inhibitors
GB9727371D0 (en) Inhibitors
GB9703335D0 (en) Inhibitors
GB9810357D0 (en) Amide derivatives
GB9810356D0 (en) Amide derivatives